Title of Invention. 5. The listing of Patent Licenses (as defined in the Collateral Agreement) should include: (a) Name and Address of Licensee/Licensor; (b) Date; (c) List of each Patent Licensed/Assigned; and (d) Description of product to which license/assignment applies
Title of Invention. 3. The listing of Patent (as defined in the Collateral Agreement) applications should include: (a) Country ; (b) Application Number; (c) Filing Date; and (d)
Title of Invention. 5. The listing of Patent Licenses (as defined in the Collateral Agreement) should include: (a) Name and Address of Licensee/Licensor; (b) Date; (c) List of each Patent Licensed/Assigned; and (d) Description of product to which license/assignment applies 6. The listing of Copyrights (as defined in the Collateral Agreement) should include: (a) Registration Number; (b) Registration Date; (c) Title as listed in Registration; (d) Publication Date; (e) Creation Date; (f) Author; and(g) Subject Matter Covered. 7. The listing of Copyright Licenses (as defined in the Collateral Agreement) should include: (a) Name and Address of Licensee/Licensor; (b) Date; (c) Work Licensed or Assigned. SCHEDULE 3.13 to Collateral Agreement Investment Property and Partnership/LLC Interests [Grantors to complete] Certificated Securities: [Grantor]: Name of Issuer Class and Series Par Value Certificate Number Percentage of Ownership Interests of such Class and Series Securities Accounts (including cash management accounts that are Investment Property) and Uncertificated Securities: [Grantor]: Financial Institution Account Number Address of Financial Institution Account Purpose Name of Issuer Class and Series Par Value Percentage of Ownership Interests of such Class and Series Partnership/LLC Interests: [Grantor]: Name of Issuer (including identification of type of entity) Type of Ownership Interest Certificate Number (if any) Percentage of Ownership Interests of such Type
Title of Invention. 4. The listing of Copyrights (as defined in the Collateral Agreement) should include: (a) Registration Number; (b) Registration Date; and (c) Title as listed in Registration.
Title of Invention. Treatment of insulin-resistant hyperglycemia by teneurin C-terminal associated peptide-1 administration
Title of Invention. Treatment of human male infertility by use of teneurin C-terminal associated peptide (TCAP)-1
Title of Invention. Edible Pet Chew with Thermo-processed Shell and Cold-formed Filling First Named Inventor/Applicant Name: Bxxxx Xxxxxx Customer Number: 167383 Filer: Lxxxx X Xxxxx Fxxxx Authorized By: Attorney Docket Number: CCon-2UTIL Receipt Date: 16-JUL-2020 Filing Date: Time Stamp: 13:21:34 Application Type: Utility under 35 USC 111(a) Payment information: Submitted with Payment yes Payment Type CARD Payment was successfully received in RAM $785 RAM confirmation Number E20207FD23294677 Deposit Account Authorized User The Director of the USPTO is hereby authorized to charge indicated fees and credit any overpayment as follows: File Listing: Document Number Document Description File Name File Size(Bytes)/ Message Digest Multi Part /.zip Pages (if appl.) 1 Application Data Sheet WebADS.pdf 115456 no 7 d6b3095ff9d177740dff54725ad9a4086027bca4 Warnings: Information: 2 specfiled.pdf 80241 yes 16 d507e51f4db57877278f7824c32e614985e5829d Multipart Description/PDF files in .zip description Document Description Start End Abstract 16 16 Warnings: Information: 3 Drawings-only black and white line drawings Presentation1.pdf 98844 no 3 4ca2e64da6c33adc80397d936bd7f05e9fc8ea56 Warnings: Information: 4 declnpoasigned.pdf 695104 yes 6 13ec6748a32327474d9cf4f6edc4def399e40bbb Multipart Description/PDF files in .zip description Document Description Start End Oath or Declaration filed 1 2
Title of Invention. LOMACEN.022PR Use of 4-Hydroxy NSAIDs for Treatment of Disease Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant to the Company’s application requesting confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. ANNEX 11 ENCORE AGREEMENT [SEE ATTACHED] Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant to the Company’s application requesting confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. EXECUTION COPY LICENSE AGREEMENT THIS LICENSE AGREEMENT (this “Agreement”) is made and entered into effective as of December 7, 2000, by and between Myriad Genetics, Inc., a Delaware corporation, having its principal place of business at 000 Xxxxxx Xxx, Xxxx Xxxx Xxxx, Xxxx 00000 (“Myriad”), and Encore Pharmaceuticals, Inc., a Delaware corporation having its principal place of business at 0000 Xxxx Xxxx Xxxxxx, Xxxx, Xxxxxxxxxx 00000 (“Licensor”).
Title of Invention. Country Filing Date Xxxxxx Case Number 2,148,395 High Repetition Rate Mid-Infrared Laser Canada 5/2/95 PREMLS.050VCA 11,234/1995 High Repetition Rate Mid-Infrared Laser Korea 5/9/95 PREMLS.050VKR 11,517/1995 Pulsed, Optically Pumped Laser And Surgical Method Using The Same Japan 5/9/95 PREMLS.050VJP SCHEDULE 16 [Intentionally Omitted] EXHIBIT A-1 PATENT ASSIGNMENT [Intentionally Omitted] EXHIBIT A-2 QUITCLAIM (Cozean to BL Acquisition) [Intentionally Omitted] EXHIBIT A-3 QUITCLAIM (PLS to BL Acquisition) [Intentionally Omitted] EXHIBIT B THE SECURITIES REPRESENTED HEREBY HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933 (THE “1933 ACT”) OR UNDER THE SECURITIES LAWS OF ANY STATE. THESE SECURITIES ARE SUBJECT TO RESTRICTIONS ON TRANSFERABILITY AND RESALE AND MAY NOT BE TRANSFERRED OR RESOLD EXCEPT AS PERMITTED UNDER THE 1933 ACT AND APPLICABLE STATE SECURITIES LAWS, PURSUANT TO REGISTRATION OR AN EXEMPTION THEREFROM. THE ISSUER OF THESE SECURITIES MAY REQUIRE AN OPINION OF COUNSEL IN FORM AND SUBSTANCE SATISFACTORY TO THE ISSUER TO THE EFFECT THAT ANY PROPOSED TRANSFER OR RESALE IS IN COMPLIANCE WITH THE 1933 ACT AND ANY APPLICABLE STATE SECURITIES LAWS. No. D1 Date of Issuance: January 24, 2005 WARRANT TO PURCHASE COMMON STOCK OF BIOLASE TECHNOLOGY, INC. This certifies that, for value received, Diodem, LLC, or its registered assigns (the “Holder”), is entitled, subject to the terms and conditions set forth below, to purchase from BIOLASE TECHNOLOGY, INC., a Delaware corporation (the “Company”), in whole or in part, Eighty-One Thousand Thirty-Seven (81,037) fully paid and nonassessable shares (the “Warrant Shares”) of the Company’s Common Stock (“Stock”). This Warrant shall be exercisable at a per share exercise price initially equal to $11.06, although such price may be adjusted as provided in Section 11 below (the “Exercise Price”).
Title of Invention. 4. The listing of Patent applications should include: (a) Application Number; (b) Filing Date; (c) Owner; (d) Inventors; and (e)
